View Older Stories View More Recent Stories

Mar 16, 2023 04:08PM Merck (MRK) Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial of MK-7684A
Mar 16, 2023 04:05PM Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small
Mar 10, 2023 06:45AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Mar 8, 2023 06:45AM Merck to Present at the Barclays 2023 Global Healthcare Conference
Mar 6, 2023 12:01PM Merck (MRK) Announces Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Mar 6, 2023 12:01PM Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Backgroun
Mar 6, 2023 12:00PM Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Mar 6, 2023 06:45AM Merck (MRK) Announces FDA Approval of Intramuscular Administration of MMRV Family of Vaccines
Mar 6, 2023 06:45AM US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measl
Mar 2, 2023 09:04AM Merck (MRK) and AstraZeneca (AZN) Provide Update on US Regulatory Review of LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone
Mar 2, 2023 09:00AM Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-
Mar 1, 2023 06:45AM Merck (MRK) Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS)
Mar 1, 2023 06:45AM Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Feb 28, 2023 06:46AM Merck (MRK) Issues Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Feb 28, 2023 06:45AM Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Feb 24, 2023 06:49AM Merck (MRK) and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO
Feb 24, 2023 06:49AM Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
Feb 22, 2023 06:47AM Merck (MRK) Opens Enrollment in New Phase 3 Trials with Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Feb 22, 2023 06:45AM Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
Feb 21, 2023 06:45AM Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
Feb 21, 2023 06:41AM Merck (MRK) Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO
Feb 21, 2023 06:40AM Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Feb 17, 2023 06:45AM Merck (MRK) Announces FDA Acceptance for Priority Review of sNDA for PREVYMIS in Cytomegalovirus Disease in Kidney Transplant Recipients
Feb 17, 2023 06:45AM U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
Feb 16, 2023 12:30PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adeno
Feb 16, 2023 10:01AM Merck (MRK) and AstraZeneca (AZN) Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial
Feb 16, 2023 10:00AM Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Feb 3, 2023 06:45AM Merck (MRK) Reports KEYTRUDA Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Feb 3, 2023 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Feb 2, 2023 06:30AM Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Jan 27, 2023 06:45AM Merck (MRK) Announces FDA Approval of KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB, II, or IIIA (NSCLC)
Jan 27, 2023 06:45AM FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell
Jan 26, 2023 08:02AM Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
Jan 25, 2023 06:50AM Merck (MRK) Announces KEYNOTE-991 Trial Evaluating KEYTRUDA Plus Enzalutamide and Androgen Deprivation Therapy
Jan 25, 2023 06:50AM Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Fut
Jan 25, 2023 06:45AM Merck's (MRK) KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival in KEYNOTE-966 Trial
Jan 25, 2023 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
Jan 24, 2023 01:19PM Merck Announces Second-Quarter 2023 Dividend
Jan 11, 2023 06:46AM Merck (MRK) completes takeover of Imago BioSciences
Jan 11, 2023 06:45AM Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
Jan 10, 2023 09:00AM Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
Jan 5, 2023 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
Jan 3, 2023 06:45AM Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 22, 2022 07:00AM Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Dec 22, 2022 06:45AM Merck (MRK) and Kelun-Biotech Enter Deal for Seven Investigational Antibody-drug Conjugate Cancer Candidates
Dec 22, 2022 06:45AM Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
Dec 21, 2022 06:45AM LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
Dec 20, 2022 06:47AM Merck (MRK), Seagen (SGEN) and Astellas Announce FDA Acceptance of sBLA for PADCEV with KEYTRUDA
Dec 20, 2022 06:45AM Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advance
Dec 20, 2022 06:45AM Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of
View More Recent Stories View Older Stories